Clinical Trial

An Exploratory Study of Cluster of Differentiation 38 (CD38) Monoclonal Antibody Combined Corticosteroid in Acquired Hemophilia A

Study acronym: AHA2023
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
To evaluate the time of response, sustained remission rate and relapse rate of CD38 monoclonal antibody (Daratumumab) combined corticosteroid in the treatment of AHA. To evaluate the safety of CD38 monoclonal antibody in the treatment of AHA.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-05-05; most recent amendment 2025-07-31.
Trial Details
NCT Number NCT05849740
Lead Sponsor Institute of Hematology & Blood Diseases Hospital, China
Conditions Acquired Hemophilia
Enrollment 25 participants
Start Date 2023-05-22
Primary Completion 2027-04-30 (estimated)
Study Completion 2027-10-31 (estimated)
Updated on ClinicalTrials.gov 2025-08-05